Overview

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.
Phase:
Phase 2
Details
Lead Sponsor:
Kastle Therapeutics, LLC
Collaborator:
Ionis Pharmaceuticals, Inc.
Treatments:
Mipomersen